The global Neurorehabilitation Therapy market size was valued at USD 1083.5 million in 2023 and is forecast to a readjusted size of USD 1861.6 million by 2030 with a CAGR of 8.0% during review period.
Neurorehabilitation is a complex medical process which aims to aid recovery from a nervous system injury, and to minimize and/or compensate for any functional alterations resulting from it.
The neurorehabilitation therapy market is driven by a growing prevalence of neurological disorders and the increasing awareness of the importance of rehabilitation in improving the quality of life for affected individuals. Advances in medical technology and therapies, such as robotics, virtual reality, and neurostimulation, have expanded the possibilities for neurorehabilitation, fostering market growth. However, challenges in this market include the high cost of advanced rehabilitation technologies and therapies, limited accessibility to specialized rehabilitation centers in some regions, and the need for skilled healthcare professionals. Additionally, the effectiveness of neurorehabilitation can vary among individuals, making it essential to tailor therapies to each patient's specific needs and conditions. Ongoing research and innovations in both treatment approaches and cost-effective solutions are crucial to addressing these challenges and further advancing the field of neurorehabilitation therapy.
This report includes an overview of the development of the Neurorehabilitation Therapy industry chain, the market status of General Hospital (Brain Injury, Spinal Cord Injury), Rehabilitation Specialist Hospital (Brain Injury, Spinal Cord Injury), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neurorehabilitation Therapy.
Regionally, the report analyzes the Neurorehabilitation Therapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neurorehabilitation Therapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Neurorehabilitation Therapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neurorehabilitation Therapy industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Brain Injury, Spinal Cord Injury).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neurorehabilitation Therapy market.
Regional Analysis: The report involves examining the Neurorehabilitation Therapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neurorehabilitation Therapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Neurorehabilitation Therapy:
Company Analysis: Report covers individual Neurorehabilitation Therapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neurorehabilitation Therapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (General Hospital, Rehabilitation Specialist Hospital).
Technology Analysis: Report covers specific technologies relevant to Neurorehabilitation Therapy. It assesses the current state, advancements, and potential future developments in Neurorehabilitation Therapy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neurorehabilitation Therapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Neurorehabilitation Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Brain Injury
Spinal Cord Injury
Peripheral Nerve Injury
Other
麻豆原创 segment by Application
General Hospital
Rehabilitation Specialist Hospital
Community Rehabilitation Center
麻豆原创 segment by players, this report covers
VISHEE
Beijing Bo'ai Hospital
Beijing Rehabilitation Hospital of Capital Medical University
NCC
CHIEFTAIN
Tongji Hospital
Haobro Medical Device
DIH
Sun Java
Aoyang Health
PKUCare Rehabilitation Hospital
Beijing Puhua International Hospital
Xiangyu Medical
Beijing United Family Rehabilitation Hospital
Bionik Laboratories Corp
BioScience Managers Ltd
Bioventus
DIH (Hocoma AG)
Ekso Bionics Holdings
Eodyne
Neofect
Neuro Rehab VR
Reha Technology AG
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Neurorehabilitation Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neurorehabilitation Therapy, with revenue, gross margin and global market share of Neurorehabilitation Therapy from 2019 to 2024.
Chapter 3, the Neurorehabilitation Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Neurorehabilitation Therapy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurorehabilitation Therapy.
Chapter 13, to describe Neurorehabilitation Therapy research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Neurorehabilitation Therapy
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Neurorehabilitation Therapy by Type
1.3.1 Overview: Global Neurorehabilitation Therapy 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Neurorehabilitation Therapy Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Brain Injury
1.3.4 Spinal Cord Injury
1.3.5 Peripheral Nerve Injury
1.3.6 Other
1.4 Global Neurorehabilitation Therapy 麻豆原创 by Application
1.4.1 Overview: Global Neurorehabilitation Therapy 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 General Hospital
1.4.3 Rehabilitation Specialist Hospital
1.4.4 Community Rehabilitation Center
1.5 Global Neurorehabilitation Therapy 麻豆原创 Size & Forecast
1.6 Global Neurorehabilitation Therapy 麻豆原创 Size and Forecast by Region
1.6.1 Global Neurorehabilitation Therapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Neurorehabilitation Therapy 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Neurorehabilitation Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Neurorehabilitation Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Neurorehabilitation Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Neurorehabilitation Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Neurorehabilitation Therapy 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 VISHEE
2.1.1 VISHEE Details
2.1.2 VISHEE Major Business
2.1.3 VISHEE Neurorehabilitation Therapy Product and Solutions
2.1.4 VISHEE Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 VISHEE Recent Developments and Future Plans
2.2 Beijing Bo'ai Hospital
2.2.1 Beijing Bo'ai Hospital Details
2.2.2 Beijing Bo'ai Hospital Major Business
2.2.3 Beijing Bo'ai Hospital Neurorehabilitation Therapy Product and Solutions
2.2.4 Beijing Bo'ai Hospital Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Beijing Bo'ai Hospital Recent Developments and Future Plans
2.3 Beijing Rehabilitation Hospital of Capital Medical University
2.3.1 Beijing Rehabilitation Hospital of Capital Medical University Details
2.3.2 Beijing Rehabilitation Hospital of Capital Medical University Major Business
2.3.3 Beijing Rehabilitation Hospital of Capital Medical University Neurorehabilitation Therapy Product and Solutions
2.3.4 Beijing Rehabilitation Hospital of Capital Medical University Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Beijing Rehabilitation Hospital of Capital Medical University Recent Developments and Future Plans
2.4 NCC
2.4.1 NCC Details
2.4.2 NCC Major Business
2.4.3 NCC Neurorehabilitation Therapy Product and Solutions
2.4.4 NCC Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 NCC Recent Developments and Future Plans
2.5 CHIEFTAIN
2.5.1 CHIEFTAIN Details
2.5.2 CHIEFTAIN Major Business
2.5.3 CHIEFTAIN Neurorehabilitation Therapy Product and Solutions
2.5.4 CHIEFTAIN Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 CHIEFTAIN Recent Developments and Future Plans
2.6 Tongji Hospital
2.6.1 Tongji Hospital Details
2.6.2 Tongji Hospital Major Business
2.6.3 Tongji Hospital Neurorehabilitation Therapy Product and Solutions
2.6.4 Tongji Hospital Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Tongji Hospital Recent Developments and Future Plans
2.7 Haobro Medical Device
2.7.1 Haobro Medical Device Details
2.7.2 Haobro Medical Device Major Business
2.7.3 Haobro Medical Device Neurorehabilitation Therapy Product and Solutions
2.7.4 Haobro Medical Device Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Haobro Medical Device Recent Developments and Future Plans
2.8 DIH
2.8.1 DIH Details
2.8.2 DIH Major Business
2.8.3 DIH Neurorehabilitation Therapy Product and Solutions
2.8.4 DIH Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 DIH Recent Developments and Future Plans
2.9 Sun Java
2.9.1 Sun Java Details
2.9.2 Sun Java Major Business
2.9.3 Sun Java Neurorehabilitation Therapy Product and Solutions
2.9.4 Sun Java Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Sun Java Recent Developments and Future Plans
2.10 Aoyang Health
2.10.1 Aoyang Health Details
2.10.2 Aoyang Health Major Business
2.10.3 Aoyang Health Neurorehabilitation Therapy Product and Solutions
2.10.4 Aoyang Health Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Aoyang Health Recent Developments and Future Plans
2.11 PKUCare Rehabilitation Hospital
2.11.1 PKUCare Rehabilitation Hospital Details
2.11.2 PKUCare Rehabilitation Hospital Major Business
2.11.3 PKUCare Rehabilitation Hospital Neurorehabilitation Therapy Product and Solutions
2.11.4 PKUCare Rehabilitation Hospital Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 PKUCare Rehabilitation Hospital Recent Developments and Future Plans
2.12 Beijing Puhua International Hospital
2.12.1 Beijing Puhua International Hospital Details
2.12.2 Beijing Puhua International Hospital Major Business
2.12.3 Beijing Puhua International Hospital Neurorehabilitation Therapy Product and Solutions
2.12.4 Beijing Puhua International Hospital Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Beijing Puhua International Hospital Recent Developments and Future Plans
2.13 Xiangyu Medical
2.13.1 Xiangyu Medical Details
2.13.2 Xiangyu Medical Major Business
2.13.3 Xiangyu Medical Neurorehabilitation Therapy Product and Solutions
2.13.4 Xiangyu Medical Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Xiangyu Medical Recent Developments and Future Plans
2.14 Beijing United Family Rehabilitation Hospital
2.14.1 Beijing United Family Rehabilitation Hospital Details
2.14.2 Beijing United Family Rehabilitation Hospital Major Business
2.14.3 Beijing United Family Rehabilitation Hospital Neurorehabilitation Therapy Product and Solutions
2.14.4 Beijing United Family Rehabilitation Hospital Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 Beijing United Family Rehabilitation Hospital Recent Developments and Future Plans
2.15 Bionik Laboratories Corp
2.15.1 Bionik Laboratories Corp Details
2.15.2 Bionik Laboratories Corp Major Business
2.15.3 Bionik Laboratories Corp Neurorehabilitation Therapy Product and Solutions
2.15.4 Bionik Laboratories Corp Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.15.5 Bionik Laboratories Corp Recent Developments and Future Plans
2.16 BioScience Managers Ltd
2.16.1 BioScience Managers Ltd Details
2.16.2 BioScience Managers Ltd Major Business
2.16.3 BioScience Managers Ltd Neurorehabilitation Therapy Product and Solutions
2.16.4 BioScience Managers Ltd Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.16.5 BioScience Managers Ltd Recent Developments and Future Plans
2.17 Bioventus
2.17.1 Bioventus Details
2.17.2 Bioventus Major Business
2.17.3 Bioventus Neurorehabilitation Therapy Product and Solutions
2.17.4 Bioventus Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.17.5 Bioventus Recent Developments and Future Plans
2.18 DIH (Hocoma AG)
2.18.1 DIH (Hocoma AG) Details
2.18.2 DIH (Hocoma AG) Major Business
2.18.3 DIH (Hocoma AG) Neurorehabilitation Therapy Product and Solutions
2.18.4 DIH (Hocoma AG) Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.18.5 DIH (Hocoma AG) Recent Developments and Future Plans
2.19 Ekso Bionics Holdings
2.19.1 Ekso Bionics Holdings Details
2.19.2 Ekso Bionics Holdings Major Business
2.19.3 Ekso Bionics Holdings Neurorehabilitation Therapy Product and Solutions
2.19.4 Ekso Bionics Holdings Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.19.5 Ekso Bionics Holdings Recent Developments and Future Plans
2.20 Eodyne
2.20.1 Eodyne Details
2.20.2 Eodyne Major Business
2.20.3 Eodyne Neurorehabilitation Therapy Product and Solutions
2.20.4 Eodyne Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.20.5 Eodyne Recent Developments and Future Plans
2.21 Neofect
2.21.1 Neofect Details
2.21.2 Neofect Major Business
2.21.3 Neofect Neurorehabilitation Therapy Product and Solutions
2.21.4 Neofect Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.21.5 Neofect Recent Developments and Future Plans
2.22 Neuro Rehab VR
2.22.1 Neuro Rehab VR Details
2.22.2 Neuro Rehab VR Major Business
2.22.3 Neuro Rehab VR Neurorehabilitation Therapy Product and Solutions
2.22.4 Neuro Rehab VR Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.22.5 Neuro Rehab VR Recent Developments and Future Plans
2.23 Reha Technology AG
2.23.1 Reha Technology AG Details
2.23.2 Reha Technology AG Major Business
2.23.3 Reha Technology AG Neurorehabilitation Therapy Product and Solutions
2.23.4 Reha Technology AG Neurorehabilitation Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.23.5 Reha Technology AG Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Neurorehabilitation Therapy Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Neurorehabilitation Therapy by Company Revenue
3.2.2 Top 3 Neurorehabilitation Therapy Players 麻豆原创 Share in 2023
3.2.3 Top 6 Neurorehabilitation Therapy Players 麻豆原创 Share in 2023
3.3 Neurorehabilitation Therapy 麻豆原创: Overall Company Footprint Analysis
3.3.1 Neurorehabilitation Therapy 麻豆原创: Region Footprint
3.3.2 Neurorehabilitation Therapy 麻豆原创: Company Product Type Footprint
3.3.3 Neurorehabilitation Therapy 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Neurorehabilitation Therapy Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Neurorehabilitation Therapy 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Neurorehabilitation Therapy Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Neurorehabilitation Therapy 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Neurorehabilitation Therapy Consumption Value by Type (2019-2030)
6.2 North America Neurorehabilitation Therapy Consumption Value by Application (2019-2030)
6.3 North America Neurorehabilitation Therapy 麻豆原创 Size by Country
6.3.1 North America Neurorehabilitation Therapy Consumption Value by Country (2019-2030)
6.3.2 United States Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Neurorehabilitation Therapy Consumption Value by Type (2019-2030)
7.2 Europe Neurorehabilitation Therapy Consumption Value by Application (2019-2030)
7.3 Europe Neurorehabilitation Therapy 麻豆原创 Size by Country
7.3.1 Europe Neurorehabilitation Therapy Consumption Value by Country (2019-2030)
7.3.2 Germany Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Neurorehabilitation Therapy Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Neurorehabilitation Therapy Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Neurorehabilitation Therapy 麻豆原创 Size by Region
8.3.1 Asia-Pacific Neurorehabilitation Therapy Consumption Value by Region (2019-2030)
8.3.2 China Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Neurorehabilitation Therapy Consumption Value by Type (2019-2030)
9.2 South America Neurorehabilitation Therapy Consumption Value by Application (2019-2030)
9.3 South America Neurorehabilitation Therapy 麻豆原创 Size by Country
9.3.1 South America Neurorehabilitation Therapy Consumption Value by Country (2019-2030)
9.3.2 Brazil Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Neurorehabilitation Therapy Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Neurorehabilitation Therapy Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Neurorehabilitation Therapy 麻豆原创 Size by Country
10.3.1 Middle East & Africa Neurorehabilitation Therapy Consumption Value by Country (2019-2030)
10.3.2 Turkey Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Neurorehabilitation Therapy 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Neurorehabilitation Therapy 麻豆原创 Drivers
11.2 Neurorehabilitation Therapy 麻豆原创 Restraints
11.3 Neurorehabilitation Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Neurorehabilitation Therapy Industry Chain
12.2 Neurorehabilitation Therapy Upstream Analysis
12.3 Neurorehabilitation Therapy Midstream Analysis
12.4 Neurorehabilitation Therapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
VISHEE
Beijing Bo'ai Hospital
Beijing Rehabilitation Hospital of Capital Medical University
NCC
CHIEFTAIN
Tongji Hospital
Haobro Medical Device
DIH
Sun Java
Aoyang Health
PKUCare Rehabilitation Hospital
Beijing Puhua International Hospital
Xiangyu Medical
Beijing United Family Rehabilitation Hospital
Bionik Laboratories Corp
BioScience Managers Ltd
Bioventus
DIH (Hocoma AG)
Ekso Bionics Holdings
Eodyne
Neofect
Neuro Rehab VR
Reha Technology AG
听
听
*If Applicable.
